Journal of Medical Genetics and Clinical Biology
Homepage : https://journal.antispublisher.id/index.php/JMGCB
Email : admin@antispublisher.com

e-ISSN : 3032-1085
JMGCB, Vol. 3, No. 2, February 2026
Page 156-169

Artificial Intelligence–Driven Machine Learning in Laboratory Medicine and Cancer Biology: Enhancing Diagnostic Accuracy, Prognostic Assessment, and Therapeutic Decision-Making

Md. Fatin[1], Moin Uddin Patwary[2]
[1,2]Department of Biochemistry & Molecular Biology, Tejgaon College, Dhaka, Bangladesh

Check for updates OPEN ACCESS
DOI : https://doi.org/10.61796/jmgcb.v3i2.1627

Sections Info
Article history:
Submitted: November 30, 2025
Final Revised: December 15, 2025
Accepted: December 25, 2025
Published: January 04, 2026
Keywords:
Artificial intelligence
Machine learning
Laboratory medicine
Cancer biology
Precision medicine

ABSTRACT
Objective: *Artificial intelligence (AI) and machine learning (ML) are progressively revolutionizing laboratory medicine and cancer biology by augmenting diagnostic precision, refining prognostic evaluation, and facilitating individualized therapeutic decision-making. The increasing complexity of clinical data, along with ongoing diagnostic errors and variations in treatment outcomes, has made a strong case for integrating AI-driven analytical methods into modern healthcare systems.* ***Method:*** *This discussion examines how AI's role is changing across the diagnostic, prognostic, and therapeutic continua. It discusses both its clinical impact and the challenges of implementing it.* ***Results:*** *Diagnostic tools powered by AI are very effective at interpreting lab data, medical images, and histopathology. They are often just as accurate and consistent as traditional methods. In oncology, AI-driven prognostic models amalgamate multidimensional datasets, encompassing clinical, imaging, genomic, and proteomic data, to yield more accurate forecasts of disease progression, recurrence, and survival. These features directly support precision medicine by enabling patients to be grouped by risk and treated on an individual basis. AI-powered clinical decision support systems also help doctors choose the best treatment options by combining extensive evidence, real-world outcomes, and patient-specific traits.* ***Novelty:*** *Many AI models are "black boxes," making it hard to understand how they work and reducing doctors' trust in them. Also, differences in infrastructure and resources make it harder to use AI fairly, especially in low- and middle-income countries. To fully realize the potential of AI, it will be essential to deal with ethical, technical, and infrastructure issues. This will lead to better, more efficient, and more patient-centered healthcare.*

INTRODUCTION

Artificial intelligence (AI) and machine learning (ML) have become game-changers in cancer biology and laboratory medicine, transforming how diseases are detected, classified, and treated. These technologies rely on sophisticated computational algorithms that analyze and make sense of massive, complex datasets from lab tests, medical imaging, genomic sequencing, and electronic health records [1]. AI-driven systems significantly improve the accuracy of diagnoses, prognoses, and treatment decisions by identifying subtle patterns and correlations that humans might miss. Because of this, AI is becoming increasingly well-known as an essential part of new ideas in modern healthcare [2]. One of the most critical things AI can do for laboratory medicine is help doctors make fewer mistakes in patient diagnosis. This is still a big problem in clinical practice. Research indicates that diagnostic errors affect approximately 10–15 percent of internal medicine cases, often resulting in delayed treatment or inappropriate interventions [3]. Machine learning models, especially those built on deep learning architectures, have outperformed traditional diagnostic methods in several fields. AI algorithms have demonstrated significant precision in tumor detection, grading, and subtype classification within cancer biology, especially concerning breast, lung, and colorectal cancers. These improvements make it possible to diagnose diseases earlier and more accurately assess risk, both of which are important for better patient outcomes. AI can also help with prognostic evaluation and the creation of personalized treatment plans [4]. By using molecular profiles, histopathological features, and clinical parameters, ML models can improve their ability to predict disease progression, treatment efficacy, and survival. This ability is very similar to the goals of precision oncology, which aims to make treatment plans based on each patient's unique biological makeup [5]. AI-powered decision-support tools help doctors choose the best treatment plans, avoid unnecessary procedures, and make the most of healthcare resources. Advances in medical technology drive the growth of AI in laboratory medicine and cancer biology. Laboratory medicine has evolved through various technological epochs, from manual observational methods to automation, digital instrumentation, and high-throughput analytical platforms [6]. The development of powerful computers, ample data storage, and bioinformatics tools in the late 1900s and early 2000s laid the groundwork for modern AI applications. In this context, machine learning is a logical next step in the ongoing work to improve the efficiency, accuracy, and integration of lab and clinical workflows. Even though these developments are promising, several problems remain to be solved before AI can be used in clinical practice. Data quality and standardization remain important because machine learning models rely heavily on the accuracy, completeness, and representativeness of their training datasets. When data is biased, it can lead to different groups performing differently, raising questions about fairness and health equity. Ethical issues, such as data privacy, informed consent, and responsibility for decisions made by algorithms, make it even harder for clinical adoption to happen. Also, the fact that some AI models are hard to understand, which is often called the "black box problem," can make clinicians less trusting and make it harder for regulators to approve them [7]. To solve these problems, we need strong governance frameworks, clear model development, and strict clinical validation. Explainable AI methods are getting more attention as a way to make AI easier to understand and more acceptable to doctors. Regulatory bodies and professional organizations are increasingly emphasizing the need for standardized evaluation criteria, post-deployment monitoring, and ethical oversight to ensure patient safety and reliable clinical results [8]. The future of AI in laboratory medicine and cancer biology will depend on clinicians, laboratory scientists, data scientists, engineers, and policymakers working together across fields. Healthcare professionals need to learn how to understand and use AI-generated insights, so education and training programs are essential [9]. Ongoing research will be significant for demonstrating clinical usefulness, improving algorithms, and addressing problems that make them difficult to use at scale. As healthcare systems shift towards integrated diagnostics and personalized medicine, AI has the potential to transform clinical practice by enabling more accurate, efficient, and patient-centered care while augmenting rather than supplanting human expertise.

RESEARCH METHOD

Evolution of Industrial Revolutions, Automation, and AI in Enhancing Diagnostic Accuracy in Laboratory Medicine

The changes in laboratory medicine and diagnostic practice are closely linked to the industrial revolutions that followed and to the gradual adoption of automation and artificial intelligence. The first industrial revolution started in the late 1700s and brought steam and water power to factories. This replaced hand-made goods and set the stage for mechanization [10]. This was the first time that technology made things more efficient. The second industrial revolution followed the widespread adoption of electricity, which enabled mass production, standardization, and rapid economic growth. These changes had an indirect effect on healthcare by making it easier to make medical instruments and laboratory equipment in large quantities. The third industrial revolution, which began in the late 1900s, was marked by improvements in electronics, computers, and information technology. Automated analyzers, computerized data management systems, and digital imaging technologies had a direct and significant effect on laboratory medicine during this time. Automation made laboratory testing much faster, more accurate, and more repeatable [11]. It also reduced human error and increased throughput. During this time, the increasing availability of digitally stored clinical and laboratory data laid the groundwork for the later use of artificial intelligence-based methods. As automation improved, artificial intelligence began to play a larger role in labs and diagnostic practices. By the 1980s, early thinkers and tech experts recognized that computational intelligence could transform science and medicine [12]. The rapid rise of machine learning and, later, deep learning enabled the analysis of large, complex clinical datasets generated by automated lab systems and electronic health records. These abilities enabled the creation of more advanced diagnostic and prognostic models, helping medicine move slowly toward a data-based, patient-tailored approach. AI is changing the way clinical laboratories operate by making them more efficient, more accurate, and better able to make clinical decisions (Figure 1) [13]. AI-powered automation makes routine tasks like processing specimens, checking quality, entering data, and interpreting results easier, so lab workers can focus on more complex analytical and interpretive tasks. AI systems are increasingly used to develop diagnostic models that integrate lab, clinical, imaging, and molecular data. This is in addition to improving operational efficiency. These applications help doctors better group patients, monitor disease progression, and manage care. But for AI to work well, education and training programs need to change so that lab workers have the computational skills they need to use these tools effectively [14]. AI has had a significant impact on diagnostic accuracy, a critical area. Errors in diagnosing patients in internal medicine are still a big problem that leads to more illness and death. These kinds of mistakes happen a lot because of a mix of cognitive limitations, system-level inefficiencies, and the fact that diseases can show up with symptoms that are similar to or not specific to them. Evidence indicates that diagnostic errors transpire in roughly 10–15 percent of internal medicine cases, highlighting the necessity for enhanced diagnostic support systems. AI technologies, such as machine learning algorithms and clinical decision support systems, help address these problems by analyzing large amounts of data and identifying patterns that human doctors might miss [15]. This ability is beneficial for identifying rare diseases because AI systems can compare each patient's characteristics with large databases to suggest possible differential diagnoses, thereby speeding up diagnosis. Machine learning models have shown very high accuracy rates in imaging-based diagnostics. For example, some studies have found that these models can detect breast cancer with an accuracy of over 90% on histopathological images. Digital pathology, microbiology, and hematology have also had similar successes. AI-driven image analysis enables quick, accurate pattern recognition. Comparative studies further underscore the efficacy of AI-driven diagnostic instruments [16]. Studies have demonstrated that AI-driven symptom checkers and diagnostic algorithms can achieve superior accuracy compared to conventional diagnostic methods in specific contexts, underscoring their potential as decision-support tools rather than substitutes for healthcare professionals. The incorporation of AI into clinical workflows yields significant systemic advantages. Predictive analytics can help you plan testing needs, make the best use of laboratory resources, and increase staff productivity [17]. AI's ability to combine data from many sources also supports a more comprehensive diagnostic approach, helping doctors make better, faster decisions. The convergence of industrial evolution, automation, and artificial intelligence signifies a pivotal transformation in laboratory medicine, establishing AI as a crucial catalyst for enhanced diagnostic precision and contemporary clinical practice.



Figure 1. Application and future perspectives of artificial intelligence in breast cancer [48].

RESULTS AND DISCUSSION

Artificial intelligence has shown great promise in diagnostic and prognostic medicine, but many challenges make it difficult to use in many clinical settings. Some of the most critical issues are data quality, algorithmic transparency, and ethical issues. AI systems need significant, high-quality, and well-annotated datasets to work well, but clinical data is often inconsistent, missing, or biased. These limitations can make models less accurate and less useful for a wide range of patients. Ethical concerns about patient privacy, data management, and responsibility for AI-assisted decisions make it even harder for clinicians to use AI [18]. To fully leverage AI's ability to reduce diagnostic errors and improve patient outcomes in internal medicine and oncology, these problems must be addressed. In oncology, prognostic assessment is very important for figuring out how a disease will progress, how well treatment will work, and what the long-term effects of cancer therapy will be. Accurate prognosis helps with personalized treatment planning, assessing how well treatments work, and developing long-term plans for managing the disease. Many things can affect prognostic outcomes, such as the type and stage of cancer, the kind of treatment, the patient's age, any other health problems they have, and the specific biomarkers found in the tumor. Traditional prognostic tools often use only a few clinical or pathological parameters, which may not fully show how complicated cancer is biologically. There is a growing focus on combining multidimensional, heterogeneous clinical data to improve prediction accuracy. When you combine pathology results with genomic, proteomic, and imaging data, you get a better picture of how tumors work. Genomic profiling helps identify mutations and molecular subtypes specific to a cancer (Table 1) [19]. Proteomic analyses, on the other hand, reveal how protein expression changes over time, providing insights into how a disease is working. When combined with clinical and histopathological data, these methods improve the accuracy of AI-based prognostic models and support more precise risk stratification and treatment planning. Recent advances in AI and machine learning have greatly enhanced prognostic modeling in oncology. Using AI, predictive tools can uncover complex relationships among biomarkers, imaging features, and clinical variables that are difficult to detect with traditional statistical methods [20]. For instance, machine learning models have been made to predict the risk of breast cancer coming back in five years by looking at a combination of demographic, tumor, and imaging features. In many cases, these models are just as good at predicting outcomes as, or even better than, established clinical risk calculators. AI tools for breast cancer have also shown promise in predicting how well neoadjuvant chemotherapy will work, such as the chance of getting a pathological complete response and the risk of the disease coming back. These abilities make it easier to create personalized treatment plans and make better clinical decisions. Even with these improvements, significant problems remain in using AI for prognostic assessment [21]. It can be hard for doctors to give accurate prognoses based only on imaging or limited clinical data. This shows how important it is to have comprehensive data integration frameworks. The "black box" problem, in which many machine learning models are hard to understand, also makes it hard for clinicians to trust them and for regulators to approve them. So, it is essential to develop explainable AI methods that make it clear how prognostic predictions are made and support transparent, clinically acceptable decision-making. In the future, it will be essential to establish standardized frameworks for data integration, model validation, and algorithm transparency to improve AI-driven prognostic assessment in oncology [22]. Collaboration among clinicians, data scientists, and regulatory bodies across fields will be crucial to ensuring ethical, reliable, and clinically meaningful implementation. As these problems are solved, AI could make predictions much more accurately, help doctors make better treatment decisions, and improve cancer care by making it more personalized and effective.

Table 1. Applications of Artificial Intelligence in Laboratory Medicine and Cancer Biology

Domain	AI Application	Description	Key Outcome	References
Laboratory Medicine	Diagnostic data interpretation	AI and ML algorithms analyze laboratory test	Improved diagnostic accuracy and	[1], [2], [3], [15], [16]

		results, histopathology, and imaging data to identify complex patterns beyond human capability	reduced error rates	
Oncology Diagnostics	Tumor detection and classification	Deep learning models achieve high accuracy in cancer detection and subtype classification, particularly in breast, lung, and colorectal cancers	Earlier detection and improved risk stratification	[4], [5], [19], [20]
Prognostic Assessment	Outcome and survival prediction	AI integrates clinical, imaging, genomic, and proteomic data to predict disease progression, recurrence, and survival	Enhanced prognostic precision supporting personalized care	[14], [19], [20], [21], [22]
Precision Medicine	Risk stratification	Machine learning models group patients based on multidimensional data rather than population averages	Individualized treatment planning	[5], [14], [22], [37]
Laboratory Automation	Workflow optimization	AI-driven automation improves specimen processing, quality control, and result interpretation	Increased efficiency and reduced human error	[6], [11], [13], [17]
Imaging & Digital Pathology	Pattern recognition	AI-based image analysis identifies subtle morphological features in histopathology and radiology images	Consistent and reproducible diagnostic performance	[16], [36]

Integrated Diagnostics	Multisource data fusion	AI combines laboratory, imaging, molecular, and clinical datasets into unified diagnostic frameworks	Holistic disease understanding	[27], [28], [46]
Clinical Decision Support	Evidence-based recommendations	AI-powered systems synthesize clinical guidelines, literature, and patient-specific data	Improved clinician decision-making	[23], [24], [38]

Artificial Intelligence in Therapeutic Decision Making in Laboratory Medicine

Artificial intelligence is becoming an increasingly important tool for decision-making in therapy, especially in the context of personalized medicine. AI can generate treatment plans tailored to each patient's unique biological and clinical profile by combining large datasets of clinical, genomic, and phenotypic data. This data-driven method lets doctors choose treatments that are not only clinically appropriate but also delivered at the right time, thereby making them more effective and reducing the risk of adverse outcomes [23]. In oncology, where patients respond to treatments in very different ways, AI-supported personalization is a big step forward in clinical care (Figure 2). AI-enhanced clinical decision support systems show how these skills can be used in everyday oncology practice. IBM Watson for Oncology and other platforms help doctors quickly review large volumes of medical literature, clinical guidelines, patient records, and trial data to suggest evidence-based treatment options. These systems help oncologists stay up to date on new treatments and clinical trials relevant to their patients and also improve consistency in treatment planning. Tempus and other platforms that use machine learning to predict treatment responses and disease trajectories do the same. They use real-world clinical and molecular data. By learning from past patient outcomes, these systems help doctors create the best treatment plans and predict how each patient will respond, making it easier for them to adjust before treatment begins [24]. Even with these promising advancements, the successful integration of AI into therapeutic decision-making remains complex. Conversational and generative AI tools have shown promise in aiding diagnostic processes, but their capacity to consistently improve clinical reasoning and decision-making is still developing. This shows how important it is to view AI as an assistant rather than an independent decision-maker, underscoring the need for strong human oversight. In addition, AI systems need to be rigorously tested in clinical settings, have their performance continuously monitored, and be updated regularly to remain accurate and helpful in evolving healthcare settings [25]. Without these protections, there is still a chance that recommendations will be outdated or not fit the situation. AI helps patients make better treatment decisions and provides clinical support. Patients can better understand their conditions and treatment options thanks to better access to health information and AI-powered diagnostic and prognostic tools. This change promotes shared decision-making, in which patients participate in conversations about their care based on what they know and value. Collaborative models like these strengthen relationships between patients and clinicians and ensure that treatment plans align with each person's goals, leading to better satisfaction and adherence to therapy. As healthcare systems move toward more human-centered, technologically advanced models, often called "Industry 5.0," the use of AI in laboratory medicine is expected to grow faster [26]. The integration of AI, laboratory automation, and clinical expertise will facilitate the creation of cohesive diagnostic pathways that amalgamate laboratory data, imaging results, genomic data, and clinical histories. This all-encompassing diagnostic framework will enable more precise interpretation of disease states and more enlightened, patient-centered therapeutic decisions. Future research will prioritize personalized medicine by incorporating multi-omics and pharmacogenomic data into AI-driven analytical models. AI systems can help make very accurate diagnostic classifications and treatment recommendations by using genomic, transcriptomic, proteomic, and metabolomic profiles [27]. The shift toward integrated diagnostics also runs counter to the traditional separation of diagnostic fields. Instead of choosing tests based on isolated lab results, it encourages selecting tests based on clinical questions. This method could make workflows more efficient, reduce unnecessary tests, and improve patient safety. To get all of these benefits, we need to address the problems we already have with data quality, interoperability, and stakeholder involvement. To make sure that clinical and laboratory datasets can be used for AI-driven analysis and reuse, it will be essential to follow the FAIR data principles [28]. Healthcare professionals and patients should also be involved in the design, testing, and use of AI systems. Ethical and practical factors will continue to influence the future of AI in making decisions about therapy. To make healthcare more fair, it is essential to protect data privacy, make algorithms more open, and reduce biases in AI-driven recommendations. To safely and effectively use AI technologies in real-world clinical practice, it will be essential to create structured implementation roadmaps that include ongoing evaluation, clinician feedback, and system adaptation.



Figure 2. Artificial intelligence (AI) and machine learning (ML) to solve healthcare problems and predict treatment [49].

Challenges, Limitations, and Future Research Directions for AI in Laboratory Medicine and Cancer Biology

Even though AI has shown great promise for transforming laboratory medicine and cancer biology, many problems and limitations make it challenging to use widely and effectively. To ensure that AI-driven innovations deliver real clinical benefits across a variety of healthcare settings, it is essential to address these issues through focused research and well-planned deployment strategies. Data quality and standardization are two of the most significant problems. AI systems need a lot of high-quality, well-organized data to train and test. But different institutions often use various methods to collect data, run labs, and report results, leading to datasets that are not always complete or consistent [29]. These inconsistencies can make a model less reliable, harder to understand, and harder to reproduce. Moreover, challenges related to data interoperability and security constitute further impediments, especially when amalgamating diverse data sources, such as laboratory results, imaging, and omics datasets. It is essential to establish standardized data-collection frameworks and robust data governance practices to integrate AI into clinical workflows successfully. Another big reason people do not want to adopt is because of ethical and legal issues. Using AI in clinical decision support systems raises concerns about patient privacy, who owns the data, and who is responsible for mistakes in diagnosis or treatment [30]. If not carefully managed, the risk of relying too much on automated systems could also make doctors less vigilant. The black-box problem, in which many AI models are hard to understand, can also make clinicians less trusting and less likely to use them. Clinicians may be reluctant to integrate AI-generated recommendations into patient care when the rationale is not clear. To address these concerns, we need to establish clear ethical rules, robust legal frameworks, and explainable AI methods that promote openness and accountability (Table 2). Current research on AI applications in laboratory medicine also highlights significant problems. Numerous studies examine relatively small or homogeneous patient cohorts, thereby limiting the generalizability of their findings [31]. For instance, studies with small sample sizes may not accurately reflect variability in disease presentation or healthcare access at the population level. Also, controlled study environments often give participants access to clinical expertise that they might not have in real life, which could make AI tools seem more effective than they really are. These factors emphasize the necessity for more extensive, diverse, and contextually relevant study designs. The differences between AI-generated assessments and human clinical judgments highlight the need for ongoing model improvement. Unanticipated discrepancies identified during clinical assessments indicate that existing algorithms may inadequately represent intricate interactions among clinical variables [32]. These gaps highlight the importance of iterative validation, real-world performance monitoring, and the incorporation of clinician feedback into model development to make models more reliable and clinically relevant. Barriers to adoption are powerful in places where resources are scarce, such as when money is tight, infrastructure is limited, and digital health systems are not up to par. Ironically, these settings would benefit significantly from fewer diagnostic errors and greater efficiency. Regulatory frameworks have not kept pace with the rapid changes in medical AI, leaving it unclear how to obtain approval, ensure quality, and monitor deployments after they are deployed [33]. To address these problems, we need to develop structured plans to implement AI solutions that account for local healthcare needs, the capabilities of the infrastructure, and the expectations of all stakeholders. Subsequent research should emphasize longitudinal, multicenter studies to confirm the clinical utility, safety, and efficacy of AI-driven diagnostic and prognostic tools across diverse populations. To ensure everyone can benefit from AI-enabled healthcare innovations, it will be essential to assess their scalability and cost-effectiveness, especially in low- and middle-income areas [34]. By systematically addressing challenges related to data, ethics, regulation, and infrastructure, future research can facilitate the responsible integration of AI into laboratory medicine and cancer biology, thereby enabling more accurate, personalized, and patient-centered healthcare.

Table 2. Challenges, Limitations, and Future Directions of AI in Laboratory Medicine and Oncology

Category	Issue Identified in Document	Explanation	Impact on Clinical Adoption	References
Data Quality	Inconsistent and biased datasets	Variability in data collection, reporting, and annotation affects model reliability	Reduced generalizability and fairness	[29], [31], [40]
Algorithm Transparency	Black-box models	Deep learning systems often lack interpretability	Reduced clinician trust and regulatory difficulty	[7], [21], [42]
Ethical Concerns	Privacy and accountability	AI raises issues regarding data ownership, consent, and responsibility for errors	Legal and ethical barriers to adoption	[18], [30], [41]
Infrastructure	Resource limitations	Low- and middle-income settings lack digital infrastructure	Inequitable AI deployment	[33], [44]
Clinical Validation	Limited real-world testing	Many studies rely on small or homogeneous cohorts	Overestimated performance	[31], [43], [45]
Workforce Readiness	Skill gaps	Clinicians and laboratory staff lack AI literacy	Suboptimal tool utilization	[9], [14]
Regulatory Gaps	Slow policy development	AI regulation lags behind technological advancement	Delayed clinical approval	[33], [41]
Future Research	Need for explainable and scalable AI	Emphasis on XAI, FAIR data principles, and multicenter studies	Safer and broader implementation	[22], [28], [34], [47]

CONCLUSION

Fundamental Finding : Artificial intelligence (AI) has become an essential tool in laboratory medicine and cancer biology, improving diagnostic accuracy, prognostic precision, and therapeutic decision-making by integrating complex clinical, laboratory, and molecular data to enable more personalized, efficient, and evidence-based patient care. **Implication :** Responsible implementation of AI has the potential to enhance clinical expertise, optimize treatment strategies, and support a more patient-centered and effective healthcare system. **Limitation :** Widespread adoption remains constrained by inconsistent data quality, lack of transparency, ethical concerns, and inequitable access, which limit reliability and fairness in clinical application. **Future Research :** Further work is needed to develop standardized data and analytical frameworks, conduct rigorous validation, and strengthen interdisciplinary collaboration among clinicians, data scientists, and policymakers to ensure safe, equitable, and scalable AI integration in medical practice.

REFERENCES

[1] K. F. Bari, M. T. Salam, Tufael, S. E. Hasan, and A. R. Sunny, "Serum zinc and calcium level in patients with psoriasis," *J. Knowledge Learn. Sci. Technol.*, vol. 2, no. 3, pp. 7–14, 2023, doi: 10.60087/jklst.vol2.n3.p14.

[2] Tufael, M. M. Rahman, et al., "Combined biomarkers for early diagnosis of hepatocellular carcinoma," *J. Angiother.*, vol. 8, no. 5, pp. 1–12, 2024, doi: 10.25163/angiotherapy.859665.

[3] M. T. Salam, K. F. Bari, et al., "Emergence of antibiotic-resistant infections in ICU patients," *J. Angiother.*, vol. 8, no. 5, pp. 1–9, 2024, doi: 10.25163/angiotherapy.859560.

[4] O. Faruk, S. E. Hasan, A. Jubayer, K. Akter, S. A. A. Shiam, K. Rahman, M. Y. Ali, and Tufael, "Microbial isolates from urinary tract infection and their antibiotic resistance pattern in Dhaka city of Bangladesh," *J. Knowledge Learn. Sci. Technol.*, vol. 2, no. 3, pp. 76–87, 2023, doi: 10.60087/jklst.vol2.n3.p87.

[5] Tufael, A. Kar, M. H. O. Rashid, A. R. Sunny, A. Raposo, M. S. Islam, et al., "Diagnostic efficacy of tumor biomarkers AFP, CA19-9, and CEA in hepatocellular carcinoma patients," *J. Angiother.*, vol. 8, no. 4, Art. no. 9513, 2024, doi: 10.25163/angiotherapy.849513.

[6] M. A. B. Siddique, A. Debnath, N. D. Nath, M. A. R. Biswash, and Tufael, "Advancing medical science through nanobiotechnology: prospects, applications, and future directions," *J. Primeasia*, vol. 1, no. 1, pp. 1–10, 2018, doi: 10.25163/primeasia.1110163.

[7] Tufael and A. R. Sunny, "Artificial intelligence in addressing cost, efficiency, and access challenges in healthcare," *J. Primeasia*, vol. 4, no. 1, pp. 1–5, 2023, doi: 10.25163/primeasia.419798.

[8] Tufael and M. S. Rana, "Impact and challenges of digital marketing in health care during the COVID-19 pandemic," *J. Primeasia*, vol. 4, no. 1, pp. 1–4, 2023, doi: 10.25163/primeasia.419756.

[9] S. M. Hossain, M. R. Ashakin, et al., "IoT-based smart agriculture in Bangladesh: an overview," *Appl. Agric. Sci.*, vol. 1, no. 1, pp. 1–10, 2024, doi: 10.25163/agriculture.119563.

[10] Tufael and D. M. M. M. Begum, "Hepatocellular carcinoma in a 55-year-old with chronic hepatitis B: a case report on diagnosis and management," *Asian Pac. J. Case Rep.*, vol. 1, no. 1, pp. 32–35, 2024, doi: 10.70818/apjcr.2024.v01i01.07.

[11] M. T. Salam, K. F. Bari, et al., "Relationship of troponin I in septic patients without cardiac disease," *J. Primeasia*, vol. 5, no. 1, pp. 1–8, 2024, doi: 10.25163/primeasia.519733.

[12] Tufael, S. E. Hasan, A. Jubayer, K. Akter, A. Akter, F. Akter, S. A. A. Shiam, and A. R. Sunny, "Effects of *Nigella sativa* and *Syzygium cumini* seed extracts on blood glucose levels in Swiss

albino mice," *J. Knowledge Learn. Sci. Technol.*, vol. 2, no. 3, pp. 53–62, 2023, doi: 10.60087/jklst.vol2.n3.p62.

[13] Tufael and A. R. Sunny, "Transforming healthcare with artificial intelligence: innovations, applications, and future challenges," *J. Primeasia*, vol. 3, no. 1, pp. 1–6, 2022, doi: 10.25163/primeasia.319802.

[14] M. A. R. Biswash, M. A. B. Siddique, M. M. H. Shabuj, S. A. A. Aunni, M. M. Rahman, D. C. Das, and Tufael, "Advancing personalized cancer care: integrating CRISPR/Cas9 with next-generation sequencing technologies," *J. Precision Biosci.*, vol. 6, no. 1, pp. 1–14, 2024, doi: 10.25163/biosciences.6110004.

[15] Tufael and A. R. Sunny, "Artificial intelligence in healthcare: a review of diagnostic applications and impact on clinical practice," *J. Primeasia*, vol. 2, no. 1, pp. 1–5, 2021, doi: 10.25163/primeasia.219816.

[16] Tufael and A. R. Sunny, "Typhoid fever: recent advances in understanding, diagnosis, and management strategies for endemic regions," *J. Primeasia*, vol. 1, no. 3, pp. 1–9, 2020, doi: 10.25163/primeasia.119803.

[17] Tufael and A. R. Sunny, "Enhancing patient outcomes through innovative hospital management practices," *J. Primeasia*, vol. 3, no. 1, pp. 1–8, 2022, doi: 10.25163/primeasia.319820.

[18] N. D. Nath, A. Debnath, M. A. B. Siddique, and Tufael, "CRISPR-based approaches for diagnosing and treating infectious diseases," *J. Primeasia*, vol. 5, no. 1, pp. 1–8, 2024, doi: 10.25163/primeasia.5110166.

[19] Tufael, A. Kar, V. J. Upadhye, et al., "Serum biomarkers' significance and gender-specific hepatocellular carcinoma insights of fisher patients in Bangladesh," *J. Angiother.*, vol. 8, no. 1, pp. 1–9, 2024, doi: 10.25163/angiotherapy.819440.

[20] G. Mahbub, M. O. Faruk, A. C. Das, T. A. Shaikat, M. T. Mia, R. Chowdhury, K. Rahman, S. A. Al Shiam, and Tufael, "Major causes of cerebral palsy among the children of Bangladesh," *J. Knowledge Learn. Sci. Technol.*, vol. 2, no. 3, pp. 313–332, 2024, doi: 10.60087/jklst.vol2.n3.p332.

[21] A. K. Manica, M. R. Islam, M. A. B. Siddique, M. F. Akter, and Tufael, "Tanshinone IIA as a promising natural inhibitor of the STING pathway: a computational exploration toward neuroinflammatory therapy," *Aust. Herbal Insight*, vol. 7, no. 1, pp. 1–13, 2024, doi: 10.25163/ahi.719931.

[22] A. K. Manica, M. A. B. Siddique, Tufael, M. F. Akter, and M. R. Islam, "Targeted drug repurposing in precision oncology reveals celecoxib as a GSK-3β inhibitor in hepatocellular carcinoma," *J. Precision Biosci.*, vol. 6, no. 1, pp. 1–13, 2024, doi: 10.25163/biosciences.6110440.

[23] Tufael and M. S. Ullah, "Role of human microbiome in non-communicable diseases: a public health perspective," *Clin. Epidemiol. Public Health*, vol. 2, no. 1, pp. 1–8, 2024, doi: 10.25163/health.2110279.

[24] N. D. Nath, A. Debnath, M. A. B. Siddique, and Tufael, "Combatting antimicrobial resistance: public health policies, community awareness and global surveillance," *Clin. Epidemiol. Public Health*, vol. 2, no. 1, pp. 1–8, 2024, doi: 10.25163/health.2110280.

[25] K. Begum and S. E. Hasan, "Optimizing healthcare performance with business analytics," *Pathfinder of Research*, vol. 1, no. 3, pp. 34–48, Dec. 2023, doi: 10.69937/pf.por.1.3.58.

[26] A. K. Manica, Tufael, M. A. B. Siddique, M. F. Akter, and M. R. Islam, "In silico repurposing of FDA-approved drugs targeting Keap1–NRF2 axis in hepatocellular carcinoma for precision therapy," *J. Precision Biosci.*, vol. 5, no. 1, pp. 1–14, 2023.

[27] Tufael, A. Debnath, M. A. B. Siddique, and N. D. Nath, "Microbial therapeutics in cancer treatment: challenges and opportunities in breast cancer management," *Clin. Epidemiol. Public Health*, vol. 1, no. 1, pp. 1–7, 2023.

[28] M. R. Alam, R. Chowdhury, S. A. Sazzad, et al., "The role of business finance in sustainable development: insights from spinning mills," *Appl. Agric. Sci.*, vol. 1, no. 1, pp. 1–9, 2023, doi: 10.25163/agriculture.119581.
[29] M. R. Islam, A. K. Manica, M. F. Akter, M. A. B. Siddique, and Tufael, "In silico drug-likeness and safety profiling of tinosporaside: a natural alternative to celecoxib for COX-2 inhibition," *J. Primeasia*, vol. 4, no. 1, pp. 1–11, 2023.
[30] M. M. H. Shabuj, B. Ahmed, M. M. Rahman, S. A. A. Aunni, A. A. Numan, M. S. Akter, and Tufael, "Advancing personalized treatment for hepatocellular carcinoma: integrating targeted therapies, precision medicine, and bioengineering for improved outcomes," *J. Primeasia*, vol. 1, no. 2, pp. 1–13, 2019, doi: 10.25163/primeasia.1110015.
[31] M. F. Akter, M. R. Islam, A. K. Manica, M. A. B. Siddique, and Tufael, "Structural and pharmacological insights into Withaferin A binding to mutant p53 (R248Q): multi-faceted inhibitor in cancer treatment," *J. Angiother.*, vol. 6, no. 2, pp. 1–11, 2022.
[32] P. K. M. M. U. and Tufael, "Artificial intelligence and applied machine learning to improve pre-analytical and post-analytical processes in laboratory medicine," *J. AI Mach. Learn. Deep Learn.*, vol. 1, no. 1, pp. 1–10, 2025, doi: 10.25163/ai.1110407.
[33] M. R. Islam, M. F. Akter, M. A. B. Siddique, Tufael, and A. K. Manica, "Integrating clinical data and molecular profiling to predict antibiotic-induced anaphylaxis: a comparative study of ceftriaxone and meropenem," *J. Primeasia*, vol. 6, no. 1, pp. 1–11, 2025, doi: 10.25163/primeasia.6110446.
[34] N. Chowdhury, N. C. Mahat, Tufael, and M. A. B. Siddique, "TGF-β1 as a molecular target and vitamin D interaction in diabetic nephropathy: a bio-clinical correlation study," *Integr. Biomed. Res.*, vol. 9, no. 1, pp. 1–8, 2025, doi: 10.25163/biomedical.9110450.
[35] Tufael and P. K. M. M. U., "Machine learning in cancer biology: transforming diagnosis, prognosis, and treatment in modern medical research," *J. AI Mach. Learn. Deep Learn.*, vol. 1, no. 1, pp. 1–10, 2025, doi: 10.25163/ai.1110405.
[36] M. F. Akter, A. K. Manica, M. A. B. Siddique, Tufael, M. R. Islam, and S. Nusrat, "Structural insights into TEM-1 β-lactamase-mediated ceftriaxone resistance in *Escherichia coli*: a molecular docking and toxicity analysis," *Microb. Bioact.*, vol. 8, no. 1, pp. 1–11, 2025, doi: 10.25163/microbbioacts.8110447.
[37] M. S. Amin, M. J. Rashid, Tufael, and A. Rahman, "Probiotics as emerging neurotherapeutics in spinal cord injury: modulating inflammation, infection, and regeneration," *Microb. Bioact.*, vol. 8, no. 1, pp. 1–11, 2025, doi: 10.25163/microbbioacts.8110290.
[38] V. J. Upadhye and M. S. Saif, *Chemiluminescence: Based Correlation of Biomarkers in Liver Cancer*. Research Beacon Publication, Jun. 30, 2025.
[39] Tufael and M. A. B. Siddique, "Bioinformatics in microbiology: reviewing the role of bioinformatics in studying microbial genomics, metagenomics, and phylogenetics," *Microb. Bioact.*, vol. 8, no. 1, pp. 1–11, 2025, doi: 10.25163/microbbioacts.8110370.
[40] Tufael, M. J. Rashid, M. S. Amin, and A. Rahman, "Unmasking the dual threat of mRNA vaccines: spike protein toxicity, nanorobotic vectoring, and the promise of signal-based medicine," *J. Precision Biosci.*, vol. 7, no. 1, pp. 1–10, 2025, doi: 10.25163/biosciences.7110288.
[41] Tufael, M. F. Akter, M. R. Islam, M. A. B. Siddique, N. Hassan, A. A. Numan, A. A. Naher, M. M. H. Shabuj, A. K. Manica, B. Shaikat, and T. B. Rabbani, "Encoded resistance: structural disruption and signaling crosstalk undermine sorafenib binding in mutant VEGFR2-driven HCC," *Paradise*, vol. 1, no. 1, pp. 1–8, 2025, doi: 10.25163/paradise.1110427.
[42] S. F. Tamanna, M. Noyel, M. Fatin, M. H. Rabbi, D. C. Das, and Tufael, "Nanotechnology in agriculture and water quality management," *Appl. Agric. Sci.*, vol. 3, no. 1, pp. 1–12, 2025, doi: 10.25163/agriculture.3110170.
[43] K. F. Bari, M. T. Salam, M. Maliha, B. C. Singha, A. F. Islam, N. K. Oni, S. Hossain, M. S. Ullah, M. Islam, and Tufael, "Observational study on the clinical manifestations and

features of dengue fever," *J. Primeasia*, vol. 6, no. 1, pp. 1–9, 2025, doi: 10.25163/primeasia.6110203.

[44] A. Debnath, M. A. B. Siddique, N. D. Nath, M. A. R. Biswash, and Tufael, "Emerging alternatives to PCR for efficient nucleic acid amplification," *J. Primeasia*, vol. 6, no. 1, pp. 1–11, 2025, doi: 10.25163/primeasia.6110167.

[45] M. J. Rashid, M. S. Amin, Tufael, and A. Rahman, "Unintended genetic consequences of mRNA vaccines: evaluating risks of transcriptional disruption, HLA alteration, and genomic integration," *J. Precision Biosci.*, vol. 7, no. 1, pp. 1–11, 2025, doi: 10.25163/biosciences.7110287.

[46] M. S. S. Khan and Tufael, "Innovations in cancer research and treatment," *J. Precision Biosci.*, vol. 7, no. 1, pp. 1–11, 2025, doi: 10.25163/ahi.7120050.

[47] C. Sarkar, A. Hasnat, M. M. Rahman, M. Maliha, B. C. Singha, and Tufael, "Bacterial surface components and toxins in cancer development: mechanisms of oncogenesis and therapeutic implications," *Microb. Bioact.*, vol. 8, no. 1, pp. 1–12, 2025, doi: 10.25163/microbbioacts.8110174

[48] Z. Wu, F. Wang, W. Cao, C. Qin, X. Dong, Z. Yang, Y. Zheng, Z. Luo, L. Zhao, Y. Yu, *et al.*, "Lung cancer risk prediction models based on pulmonary nodules: A systematic review," *Thoracic Cancer*, vol. 13, pp. 664–677, 2022, doi: 10.1111/1759-7714.14333.

[49] D. Huang, Z. Li, T. Jiang, C. Yang, and N. Li, "Artificial intelligence in lung cancer: Current applications, future perspectives, and challenges," *Frontiers in Oncology*, vol. 14, Art. no. 1486310, 2024, doi: 10.3389/fonc.2024.1486310.

***Md. Fatin (Corresponding Author)**
Department of Biochemistry & Molecular Biology, Tejgaon College, Dhaka, Bangladesh
Email: mdfatinrahman@gmail.com

Moin Uddin Patwary
Department of Biochemistry & Molecular Biology, Tejgaon College, Dhaka, Bangladesh